Dendritic cells: Tools and targets for antitumor vaccination

Expert Review of Vaccines

Volumn 4, Issue 5, 2005, Pages 699-710

  Den Brok, Martijn H M G M ^a   Nierkens, Stefan ^a   Figdor, Carl G ^a   Ruers, Theo J M ^b   Adema, Gosse J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antigen presentation; Cancer; Dendritic cells; Immunotherapy; Regulatory T cells; Toll like receptors; Vaccines

Indexed keywords

CANCER VACCINE; CD40 LIGAND MONOCLONAL ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 MONOCLONAL ANTIBODY; DENDRITIC CELL VACCINE; IMIQUIMOD; INTERLEUKIN 10; MONOCLONAL ANTIBODY; OLIGODEOXYNUCLEOTIDE; PROSTAGLANDIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIGEN PRESENTING CELL; CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL ACTIVATION; CELL MATURATION; CELL MIGRATION; DENDRITIC CELL; DRUG EFFICACY; DRUG TARGETING; EX VIVO STUDY; FEASIBILITY STUDY; GENETIC TRANSFECTION; HUMAN; IMMUNE SYSTEM; IMMUNITY; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TARGET CELL; TUMOR; TUMOR IMMUNITY; VACCINATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL DIFFERENTIATION; CELL MOVEMENT; CLINICAL TRIALS; DENDRITIC CELLS; DRUG EVALUATION, PRECLINICAL; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; T-LYMPHOCYTES;

EID: 27444442651     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.4.5.699     Document Type: Review

References (88)

1. Adams S, O'Neill DW, Bhardwaj N. Recent advances in dendritic cell biology. J. Clin. Immunol. 25(2), 87-98 (2005).
2. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nature Rev. Immunol. 5(4), 296-306 (2005).
3. McKenna K, Beignon AS, Bhardwaj N. Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol. 79(1), 17-27 (2005).
4. Schreurs MW, Eggert AA, Punt CJ, Figdor CG, Adema GJ. Dendritic cell-based vaccines: from mouse models to clinical cancer immunotherapy. Crit. Rev. Oncog. 11(1), 1-17 (2000).
5. Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol. Immunother. 46(2), 82-87 (1998).
6. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nature Med. 10(5), 475-480 (2004). Clear review detailing the latest clinical results in dendritic cell (DC) vaccination.
7. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nature Med. 10(9), 909-915 (2004).
8. De Vries IJ, Lesterhuis WJ, Scharenborg NM et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin. Cancer Res. 9(14), 5091-5100 (2003).
9. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol. Rev. 199, 251-263 (2004).
10. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. 4(3), 328-332 (1998).
11. Brossart P, Bevan MJ. Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Blood 90(4), 1594-1599 (1997).
12. van Broekhoven CL, Parish CR, Demangel C, Britton WJ, Altin JG. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res. 64(12), 4357-4365 (2004).
13. Zitvogel L, Regnault A, Lozier A et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nature Med. 4(5), 594-600 (1998).
14. + CTL responses in vivo. J. Immunol. 168(5), 2240-2246 (2002).
15. Mazzolini G, Alfaro C, Sangro B et al. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J. Clin. Oncol. 23(5), 999-1010 (2005).
16. Bevan MJ. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143(5), 1283-1288 (1976).
17. Wolkers MC, Brouwenstijn N, Bakker AH, Toebes M, Schumacher TN. Antigen bias in T cell cross-priming. Science 304(5675), 1314-1317 (2004).
18. Delamarre L, Holcombe H, Mellman I. Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J. Exp. Med. 198(1), 111-122 (2003).
19. Datta SK, Redecke V, Prilliman KR et al. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J. Immunol. 170(8), 4102-4110 (2003).
20. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nature Rev. Immunol. 3(2), 133-146 (2003).
21. Matzinger P. The danger model: a renewed sense of self. Science 296(5566), 301-305 (2002).
22. Skoberne M, Beignon AS, Bhardwaj N. Danger signals: a time and space continuum. Trends Mol. Med. 10(6), 251-257 (2004).
23. Iwasaki A, Medzhitov R. Toll-like receptor control of die adaptive immune responses. Nature Immunol. 5(10), 987-995 (2004).
24. + T cells. J. Immunol. 174(2), 710-717 (2005).
25. Akira S, Takeda K. Toll-like receptor signalling. Nature Rev. Immunol. 4(7), 499-511 (2004). Extensive review on Toll-like receptor (TLR) signaling.
26. Yarovinsky F, Zhang D, Andersen JF et al. TLR11 Activation of dendritic cells by a protozoan profilin-like protein. Science 308(5728), 1626-1629 (2005).
27. Hasan U, Chaffois C, Gaillard C et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J. Immunol. 174(5), 2942-2950 (2005).
28. Kadowaki N, Ho S, Antonenko S et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194(6), 863-869 (2001).
29. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur. J. Immunol. 31(11), 3388-3393 (2001).
30. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Ann. Rev. Immunol. 21, 685-711 (2003). Excellent review regarding the tolerogenic properties of DCs.
31. Jonuleit H, Giesecke-Tuettenberg A, Tuting T et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer 93(2), 243-251 (2001).
32. Mailliard RB, Wankowicz-Kalinska A, Cai Q et al. α-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 64(17), 5934-5937 (2004).
33. + T-cell populations lacking helper function. Nature Immunol. 6(2), 163-170 (2005). Clearly demonstrates that pathogen components are essential to efficiently direct helper T-cell differentiation.
34. Pulendran B. Variegation of the immune response with dendritic cells and pathogen recognition receptors. J. Immunol. 174(5), 2457-2465 (2005).
35. De Vries IJ, Krooshoop DJ, Scharenborg NM et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 63(1), 12-17 (2003).
36. Adema GJ, de Vries IJ, Punt CJ, Figdor CG. Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr. Opin. Immunol. 17(2), 170-174 (2005).
37. Vicari AP, Vanbervliet B, Massacrier C et al. In vivo manipulation of dendritic cell migration and activation to elicit antitumour immunity. Novartis Found Symp. 256, 241-254; discussion 254-269 (2004).
38. Forster R, Schubel A, Breitfeld D et al. CCR7 co-ordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99(1), 23-33 (1999).
39. Ohl L, Mohaupt M, Czeloth N et al. CCR7 governs skin dendritic cell migration under inflammatory and steady-state conditions. Immunity 21(2), 279-288 (2004).
40. Angeli V, Llodra J, Rong JX et al. Dyslipidemia associated with atherosclerotic disease systemically alters dendritic cell mobilization. Immunity 21(4), 561-574 (2004).
41. Katagiri K, Ohnishi N, Kabashima K et al. Crucial functions of the Rap 1 effector molecule RAPL in lymphocyte and dendritic cell trafficking. Nature Immunol. 5(10), 1045-1051 (2004).
42. Eggert AA, Schreurs MW, Boerman OC et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res. 59(14), 3340-3345 (1999).
43. Josien R, Li HL, Ingulli E et al. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J. Exp. Med. 191(3), 495-502 (2000).
44. Mullins DW, Sheasley SL, Ream RM et al. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J. Exp. Med. 198(7), 1023-1034 (2003). Demonstrates that the route of immunization of DCs affects the location of tumor immunity.
45. Binder RJ, Srivastava PK. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8(+) T cells. Nature Immunol. 6(6), 593-599 (2005).
46. Eriksson K, Sun JB, Nordstrom I et al. Coupling of antigen to cholera toxin for dendritic cell vaccination promotes the induction of MHC class I-restricted cytotoxic T cells and the rejection of a cognate antigen-expressing model tumor. Eur.J. Immunol. 34(5), 1272-1281 (2004).
47. Moron VG, Rueda P, Sedlik C, Leclerc C. In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway. J. Immunol. 171(5), 2242-2250 (2003).
48. Bonifaz LC, Bonnyay DP, Charalambous A et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199(6), 815-824 (2004). Important paper showing for the first time that in vivo antibody targeting to DCs could induce cross presentation to T-cells.
49. Hawiger D, Inaba K, Dorsett Y et al. Dendritic cells induce peripheral T cell unresponsiveness under steady-state conditions in vivo. J. Exp. Med. 194(6), 769-779 (2001).
50. + regulatory T cells by targeting of antigens to immature dendritic cells. Blood 101(12), 4862-4869 (2003).
51. Tacken PJ, de Vries IJ, Gijzen K et al. Effective induction of naive and recall T cell responses by targeting antigen to human dendritic cells via a humanized antiDC-SIGN antibody. Blood 106(4), 1278-1285 (2005).
52. Engering A, Geijtenbeek TB, van Vliet SJ et al. The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J. Immunol. 168(5), 2118-2126 (2002).
53. Ramakrishna V, Treml JF, Vitale L et al. Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs antimelanoma T cell responses via multiple HLA molecules. J. Immunol. 172(5), 2845-2852 (2004).
54. Merad M, Sugie T, Engleman EG, Fong L. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 99(5), 1676-1682 (2002).
55. Pulendran B, Banchereau J, Burkeholder S et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J. Immunol. 165(1), 566-572 (2000).
56. Furumoto K, Soares L, Engleman EG, Merad M. Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J. Clin. Invest. 113(5), 774-783 (2004). Excellent paper that uses attraction of DCs to tumor sites, in combination with TLR triggering, to induce antitumor responses.
57. Delamarre L, Pack M, Chang H, Mellman I, Trombetta ES. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science 307(5715), 1630-1634 (2005).
58. Milas L, Mason KA, Ariga H et al. CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res. 64(15), 5074-5077 (2004).
59. Weigel BJ, Rodeberg DA, Krieg AM, Blazar BR. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin. Cancer Res. 9(8), 3105-3114 (2003).
60. Voll RE, Herrmann M, Roth EA et al. Immunosuppressive effects of apoptotic cells. Nature 390(6658), 350-351 (1997).
61. Steinman RM, Turley S, Mellman I, Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J. Exp. Med. 191(3), 411-416 (2000).
62. Taylor PR, Carugati A, Fadok VA et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J. Exp. Med. 192(3), 359-366 (2000).
63. Vabulas RM, Braedel S, Hilf N et al. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J. Biol. Chem. 277(23), 20847-20853 (2002).
64. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425(6957), 516-521 (2003).
65. van Mierlo GJ, den Boer AT, Medema JP et al. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc. Natl Acad. Sci. USA 99(8), 5561-5566 (2002).
66. Salem ML, Kadima AN, Cole DJ, Gillanders WE. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J. Immunother. 28(3), 220-228 (2005).
67. Nair S, McLaughlin C, Weizer A et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J. Immunol. 171(11), 6275-6282 (2003).
68. + CTL to cause tumor eradication. J. Immunol. 173(11), 6753-6759 (2004).
69. Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr. Oncol. Rep. 6(2), 88-95 (2004).
70. Meng Y, Carpentier AF, Chen L et al. Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int. J. Cancer 166(6), 992-997 (2005).
71. Vicari AP, Ait-Yahia S, Chemin K et al. Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J. Immunol. 165(4), 1992-2000 (2000).
72. Salcedo R, Ponce ML, Young HA et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96(1), 34-40 (2000).
73. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Rev. Cancer. 5(4), 263-274 (2005).
74. Sharma S, Stolina M, Lin Y et al. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J. Immunol. 163(9), 5020-5028 (1999).
75. Vicari AP, Chiodoni C, Vaure C et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin-10 receptor antibody. J. Exp. Med. 196(4), 541-549 (2002).
76. Curiel TJ, Wei S, Dong H et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nature Med. 9(5), 562-567 (2003).
77. Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol. 17(2), 133-144 (2005).
78. Bell D, Chomarat P, Broyles D et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J. Exp. Med. 190(10), 1417-1426 (1999).
79. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nature Rev. Immunol. 4(10), 762-774 (2004).
80. + regulatory T cells in immunological tolerance to self and non-self. Nature Immunol. 6(4), 345-352 (2005).
81. Ercolini AM, Ladle BH, Manning EA et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J. Exp. Med. 201(10), 1591-1602 (2005).
82. Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23(10), 2346-2357 (2005).
83. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nature Immunol. 3(7), 611-618 (2002).
84. Sutmuller RP, van Duivenvoorde LM, van Elsas A et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194(6), 823-832 (2001).
85. Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100(14), 8372-8377 (2003).
86. Hodi FS, Mihm MC, Soiffer RJ et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA 100(8), 4712-4717 (2003). Reports on an excellent human study demonstrating the potential of cytotoxic T-lymphocyte antigen-4 blockade.
87. Mokyr MB, Kalinichenko T, Gorelik L, Bluestone JA. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res. 58(23), 5301-5304 (1998).
88. den Brok MH, Sutmuller RP, van der Voort R et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res. 64(11), 4024-4029 (2004).